NORVIR CAPSULE

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

RITONAVIR

Disponible des:

ABBVIE CORPORATION

Codi ATC:

J05AE03

Designació comuna internacional (DCI):

RITONAVIR

Dosis:

100MG

formulario farmacéutico:

CAPSULE

Composición:

RITONAVIR 100MG

Vía de administración:

ORAL

Unidades en paquete:

2X84

tipo de receta:

Prescription

Área terapéutica:

HIV PROTEASE INHIBITORS

Resumen del producto:

Active ingredient group (AIG) number: 0128780001; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2012-11-08

Fitxa tècnica

_ _
_NORVIR Product Monograph _
_Page 1 of 64 _
PRODUCT MONOGRAPH
PR
NORVIR
®
Ritonavir
film-coated tablets (100 mg)
Human Immunodeficiency Virus (HIV) Protease Inhibitor
AbbVie Corporation
Date of Revision:
8401 Trans-Canada Highway
May 29, 2019
St-Laurent, Qc H4S 1Z1
Submission Control No: 226180
_ _
_NORVIR Product Monograph _
_Page 2 of 64 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................23
DOSAGE AND ADMINISTRATION
..............................................................................42
OVERDOSAGE
................................................................................................................43
ACTION AND CLINICAL PHARMACOLOGY
............................................................44
STORAGE AND STABILITY
..........................................................................................48
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................48
PART II: SCIENTIFIC INFORMATION
................................................................................49
PHARMACEUTICAL INFORMATION
..........................................................................49
CLINICAL TRIALS
..........................................................................................................50
MICROBIOLOGY
...............